For more information visit us online now at... 
gotoper.com/go/MB19NEWS1

A Message From the Chair
Patrick I. Borgen, MD

It’s hard to believe it’s already been 7 months since the last Miami Breast Cancer Conference®. Seven months since we last gathered at the Fontainebleau in Miami Beach for 4 days of learning and celebrating the latest in breast cancer research.

2018 has already been quite the year for new data, most of which has revolved around one theme: the de-escalation of therapy. At the most recent meeting in Chicago we first heard the latest results from trials such as TAILORx and PERSPEPHONE, which are already changing the way we treat patients with early-stage breast cancer.

As exciting a time this is, with every new trial comes new questions. How the latest data impacts your practice and your patients requires a careful understanding of new data, that takes a multidisciplinary perspective into account.

The Miami Breast Cancer Conference® is a meeting uniquely positioned to provide that perspective. With faculty and learners of complex and differing backgrounds, someone in Miami will always be able to answer your questions and help with your most difficult cases. Whether it was first reported at a major meeting or the supplement of a journal, what you need to know, and how to use it, will be presented at Miami.

I can’t wait to see you there!

Patrick I. Borgen, MD
Chairman, Department of Surgery
Maimonides Hospital
Director, Brooklyn Breast Cancer Program
Brooklyn, NY
PERSEPHONE Trial Offers New Options for HER2+ Disease

For patients with HER2-positive disease, the results presented from the phase III PERSEPHONE trial showed patients with early-stage breast cancer could receive shorter treatment to achieve the same outcome. Researchers demonstrated a 6-month course of adjuvant trastuzumab was noninferior for disease-free survival (DFS) compared with the standard 12-month schedule. Overall, the 4-year DFS rate was 89.8% with 12 months of trastuzumab compared with 89.4% for patients on the 6-month arm. A full debrief on the results from this trial and how they inform your practice, will be presented at this year’s meeting.

How TAILORx is Reshaping Treatment

Perhaps the biggest news out of ASCO came from the phase III TAILORx study, which showed adjuvant endocrine therapy (ET) alone was noninferior to adjuvant ET in combination with chemotherapy for patients with hormone receptor (HR)-positive, HER2-negative, early-stage breast cancer. Patients for whom noninferiority was demonstrated had node-negative disease and an intermediate risk score for distant recurrence. Nine-year rates were similar for patients receiving ET alone and ET plus chemo, including invasive DFS (83.3% vs. 84.3%), and overall survival (93.9% vs. 93.8%). The results from TAILORx, if implemented, may save thousands of women with breast cancer from overtreatment. TAILORx study lead and lead author, Joseph A. Sparano, MD, from Albert Einstein College of Medicine, will be at Miami Breast and leading the conversation on therapy de-escalation!

ANNOUNCING THIS YEAR’S KEYNOTE SPEAKER

Dr. Gregory Stock is a biotech entrepreneur, bioethicist, and best-selling author of books such as Redesigning Humans: Our Inevitable Genetic Future and The Book of Questions. Dr. Stock, who currently serves as the Co-Director of the Mount Sinai Precision Wellness Center, is one of the leading authorities on the role of genomics in medicine. This year, at the Miami Breast Cancer Conference®, Dr. Stock will be delivering the keynote address, exploring the role of genomics in breast cancer and our everyday lives.

This year’s keynote lecture will take place on Saturday, March 9
Agenda Highlights

Friday, March 8, 2019
The US Opioid Crisis and Breast Cancer
Patrick I. Borgen, MD
TAILORx and the De-escalation of Therapy
Joseph A. Sparano, MD
Nontraditional Genetic Counseling: Solving the Challenge of the Undetected Carrier
Pat W. Whitworth, MD
CDK4/6 Inhibitors - Where Are We, and What’s Next?
Debu Tripathy, MD
Update From ESMO: Immunotherapy in Breast Cancer
Elizabeth Mittendorf, MD, PhD, & Hope S. Rugo, MD, FASCO

Saturday, March 9, 2019
State-of-the-Art Approach to MRI in Breast Cancer
Elizabeth Morris, MD, FACP, FSBI, FISMRM
Controversies in the Optimal Management of HER2+ Breast Cancer
Mark D. Pegram, MD
Surgery for the Primary in De Novo Stage IV Disease
Tari A. King, MD
Breast Cancer in Pregnancy and in Younger Women
Ann H. Partridge, MD, MPH
Medical Crossfire®: Optimal De-escalation in Patients Undergoing BCT for pN0 Breast Cancer: PBI or Omission?
Patrick I. Borgen, MD; Reshma Jagsi, MD, DPhil; and Frank A. Vicini, MD, FACP, FABS, FASTRO;
Keynote Address
Gregory Stock, PhD

Sunday, March 10, 2019
Rare Breast Cancers
David M. Euhus, MD, FACS
Physician Burnout: An Action-Oriented Roundtable Discussion
Patrick I. Borgen, MD; Anees B. Chagpar, MD, MSc, MPH, MA, MBA, FACS, FRCSC; Kelly K. Hunt, MD; and, Pat W. Whitworth, MD
The Art and Science of Survivorship Planning and Management
Ann H. Partridge, MD, MPH
REGISTER TODAY, USING CODE MB19NEWS1 TO SAVE $125

TWO WAYS TO REGISTER

Online
Visit us online at gotoper.com/go/MBCC19BRO

OR

Call
1-609-378-3701

For any other question email us at: info@gotoper.com

For more information visit us online now at...

gotoper.com/go/MB19NEWS1